These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 30797468)

  • 1. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
    Koessler T; Addeo A; Nouspikel T
    Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment and Analysis of ctDNA.
    Gilson P
    Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
    Chen S; Liu M; Zhou Y
    Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
    Valpione S; Campana L
    Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cornerstone of integrating circulating tumor DNA into cancer management.
    Li Z; Yi L; Gao P; Zhang R; Li J
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):1-11. PubMed ID: 30419316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy: unlocking the potentials of cell-free DNA.
    Chu D; Park BH
    Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies.
    Marass F; Castro-Giner F; Szczerba BM; Jahn K; Kuipers J; Aceto N; Beerenwinkel N
    Recent Results Cancer Res; 2020; 215():347-368. PubMed ID: 31605238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory.
    Nikolaev S; Lemmens L; Koessler T; Blouin JL; Nouspikel T
    Anal Biochem; 2018 Feb; 542():34-39. PubMed ID: 29137972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.
    Hahn AW; Stenehjem D; Nussenzveig R; Carroll E; Bailey E; Batten J; Maughan BL; Agarwal N
    Cancer Treat Res Commun; 2019; 19():100120. PubMed ID: 30743187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.